Market Overview

Benzinga's Volume Movers

Related VRTX
CNBC's Stock Pops & Drops From July 2
Vertex Shares Leap On FDA Approval For Cystic Fibrosis Combo ORKAMBI
Vertex Pharmaceuticals' CF Drug Orkambi Gets FDA Nod - Analyst Blog (Zacks)
TG Therapeutics to Present Clinical Data on TG-1101 and TGR-1202 at the 20th Congress of the European Hematology Association and the 13th International Congress on Malignant Lymphoma
What's Happening At The ASCO Conference?

Vertex Pharmaceuticals (NASDAQ: VRTX) shares moved up 41.68% to $94.37. The volume of Vertex Pharmaceuticals shares traded was 2978% higher than normal. Vertex Pharma reported that its two phase 3 study of Lumacaftor in combination with ivacaftor met the primary endpoint.

TG Therapeutics (NASDAQ: TGTX) shares rose 6.91% to $10.36. The volume of TG Therapeutics shares traded was 442% higher than normal. TG Therapeutics completed a licensing agreement with Ligand Pharma (NASDAQ: LGND) to develop inhibitors of IRAK4. (NASDAQ: WIX) surged 6.87% to $18.99. The volume of shares traded 333% higher than normal. announced that it had surpassed 50 million registered users worldwide.

Voxeljet AG (NASDAQ: VJET) shares climbed 3.71% to $18.15. The volume of Voxeljet shares traded was 200% higher than normal. Voxeljet's trailing-twelve-month revenue is $16.39 million.

Posted-In: volume moversNews Intraday Update Markets Movers


Related Articles (LGND + TGTX)

Around the Web, We're Loving...

Get Benzinga's Newsletters